Thank you for Subscribing to Life Science Review Weekly Brief
Comprehensive preclinical bioanalysis is key at every stage of product development.
FREMONT, CA: A bioanalytical test's results are of immense scientific value, beyond the standard criteria for performing bioanalytical research. The maximum tolerated dose of treatment can be calculated using data from bioanalytical assays on certain safety factors. To make decisions about how frequently and how much of a medication should be administered for efficacy without excessive toxicity, pharmacokinetic experts analyse the data to evaluate exposure, half-life, and other pharmacological factors as well as potential safety concerns. There are several reasons why collaborating with contract laboratories might be quite advantageous. Smaller biotechs can benefit the most from CROs because they can offer valuable advisory services and a wider range of service options, making them a one-stop-shop for all of your bioanalytical requirements. Based on the quantity and variety of assays they have created, CROs have a highly thorough understanding of bioanalysis. Since they are more regularly audited by numerous regulatory authorities, this is reflected in their scientific competence as well as their understanding of worldwide regulatory practices, and these qualities ultimately benefit all of their clients.
A drug development programme must include the validation of bioanalytical methods and controlled bioanalysis. In terms of technology platforms and laws, they have changed over time. Chemical-based therapeutic candidates have been analysed using a variety of technical platforms, including LC-UV, LC-Fluorescence, LC-MS, and LC-MS/MS. Although they have been updated to incorporate modern technologies, regulatory organisations' guidelines still need to be fully harmonised.
Bioanalysts should carefully assess the physicochemical characteristics of the target analyte, its metabolites, and assay requirements such as LLOQ, and matrix against the state-of-the-art technology platforms before beginning method development.The impact of various parameters on the assay performance should be carefully considered. The bioanalysts can then move forward with method validation and bioanalysis after the desired technique has been devised, following the various regulatory guidelines and laboratory-specific SOPs. Additionally, procedures can be changed in response to new information, such as the identification of a new metabolite that necessitates monitoring, or as more data are generated, such as clinical pharmacokinetic data from an FIH study that may result in a lower LLOQ or other unanticipated problems. It is important to realise that the creation and validation of methods is a continuous process. As drug development advances, a bioanalytical assay has a life cycle that should be science-driven.
In the discovery stage, as well as during the preclinical and clinical stages of drug development, the necessity for sound bioanalytical procedures is well acknowledged and accepted. As a result, it is widely acknowledged that sample preparation and method validation are necessary to show the method's effectiveness and the accuracy of the analytical results. Before starting the validation study, the acceptance criteria should be spelt out in a validation plan. The established assay should be sufficiently robust to allow for easy adaptation to various bioanalytical needs, such as application to a study of drug-drug interactions, toxicokinetics, or characterization of the plasma levels of the metabolites, and options for small adjustments.